APO866 an NAD+ inhibitor shows clinical activity in CTCL + B-CLL. APO866 is selected via TopoTarget's discovery technology


To NASDAQ OMX Copenhagen A/S
Announcement No. 35-08 / Copenhagen, 22 December 2008

Copenhagen, Denmark, 22 December 2008 - TopoTarget A/S (OMX: TOPO) announces an
update on phase II data with APO866 in three clinical studies. APO866 has
demonstrated a confirmed partial response (PR) in Cutaneous T-Cell Lymphoma
(CTCL) and transient reductions in white blood cells in patients with B-cell
Chronic Lymphocytic Leukaemia (B-CLL) whereas there was no clinical effect in
melanoma. APO866 -a specific inhibitor of the key enzyme involved in the
synthesis of NAD+ is administered by continuous infusion at 0.126 mg/m2/hr for
96 hours in a 28 day schedule and is reasonably well tolerated. While this
ongoing CTCL study has shown encouraging signs of clinical activity, five more
patients are required for the interim analysis. 
 
“APO0866 rights came to TopoTarget through the acquisition of Apoxis in 2007
and we have evaluated the drug in three phase II studies. I am happy to
announce that we now have evidence activity in cancer patients. APO866 has
demonstrated a confirmed PR in cutaneous T-Cell lymphoma and transient
reductions in white blood cells in patients with B-CLL”, said Peter Buhl
Jensen, Professor, MD, CEO of TopoTarget. 

“From our laboratory investigations we believed that the NAD+ target could be
very important in cancer treatment and this confirms our beliefs. It is very
difficult to find anticancer drugs with new mechanisms of action and activity
beyond models. We still have a long way to go but now we know that this target
and mechanism works also in cancer patients”, Peter Buhl Jensen further
commented. 

Today's announcement does not change TopoTarget's full-year financial guidance
for 2008. 

TopoTarget A/S

 
	
For further information, please contact:

Peter Buhl Jensen 	Telephone	+45 39 17 94 99
CEO		Mobile	+45 21 60 89 22

Attachments

announcement no  35-08 apo866 an nad inhibitor shows clinical activity in ctcl   b-cll.pdf